TENX
Tenax Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.94
+8.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 45.3M | 32.7M | 12.7M | 3.2M | 5.4M |
| SG&A Expense | 23.4M | 23.7M | 6.8M | 5.0M | 5.7M |
| General & Admin Expense | 23.4M | 23.7M | 6.8M | 5.0M | 5.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 68.6M | 56.4M | 19.5M | 8.2M | 11.1M |
| Cost and Expenses | 68.6M | 56.4M | 19.5M | 8.2M | 11.1M |
| Operating Income (EBIT) | (68.6M) | (56.4M) | (19.5M) | (8.2M) | (11.1M) |
| Non-Operating | |||||
| Interest Income | 3.8M | 3.8M | 1.9M | — | — |
| Interest Expense | — | — | 23.0K | 24.0K | 4.4K |
| Net Interest Income | 3.8M | 3.8M | 1.9M | (24.0K) | (4.4K) |
| Other Non-Op Income/Expense | 3.7M | 3.8M | 1.9M | 523.0K | 4.7K |
| Non-Operating Income (excl Interest) | (2.8M) | (3.8M) | (1.9M) | (547.0K) | (9.2K) |
| EBT (Pre-Tax Income) | (64.9M) | (52.6M) | (17.6M) | (7.7M) | (11.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (64.9M) | (52.6M) | (17.6M) | (7.7M) | (11.0M) |
| Earnings from Cont. Ops | (64.9M) | (52.6M) | (17.6M) | (7.7M) | (11.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (64.9M) | (52.6M) | (17.6M) | (7.7M) | (11.0M) |
| Per Share | |||||
| Basic EPS | ($1.49) | ($1.34) | ($1.15) | ($31.04) | ($600.80) |
| Diluted EPS | ($1.49) | ($1.34) | ($1.15) | ($31.04) | ($600.80) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 50.9M | 39.2M | 15.3M | 248447 | 18391 |
| Diluted Shares Outstanding | 50.9M | 39.2M | 15.3M | 248447 | 18391 |
| Profitability Metrics | |||||
| EBITDA | (65.8M) | (52.6M) | (17.6M) | (7.7M) | (10.9M) |
| D&A | — | — | — | 8.0K | 113.3K |
| EBIT | (65.8M) | (52.6M) | (17.6M) | (7.7M) | (11.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026